Chao Wu1, Hai-Tao Tao1, Fang-Fang Li2, Shang-Wu Huang3, Wei-Wei Dong1, Jin-Liang Wang1, Yi Hu1, Fang Li1. 1. Department of Oncology, Chinese PLA General Hospital 28 Fuxing Road, Haidian District, Beijing 100853, China. 2. Department of Health Academy, Chinese PLA General Hospital 28 Fuxing Road. 3. Department of Internal Nedicine, No.1 Rongjun Hospital of Guangdong Province Xingangxi Road, Haizhu District, Guangzhou, 510260, China.
Abstract
PURPOSE: Extramammary Paget's disease (EMPD) is a rare neoplasm with only a limited number of cases reported in the literature. Little was known about the availability of systemic chemotherapy for metastatic EMPD. METHODS: We report one case of heavily pretreated EMPD with multiple organ metastases and successfully treated by pemetrexed. RESULT: The tumor was progression after multi-line therapy including erlotinib, radiotherapy, combined chemotherapy and radioactive particles implantation. Pemetrexed monotherapy was applied and progression free survival of more than 5 months with partial remission (PR) response was achieved. Only 1 time of grade 3 neutropenia was observed during the pemetrexed chemotherapy. CONCLUSION: Due to the significant response and tolerability in the present case, pemetrexed monotherapy was recommended as a potent candidate for patients with advanced EMPD.
PURPOSE: Extramammary Paget's disease (EMPD) is a rare neoplasm with only a limited number of cases reported in the literature. Little was known about the availability of systemic chemotherapy for metastatic EMPD. METHODS: We report one case of heavily pretreated EMPD with multiple organ metastases and successfully treated by pemetrexed. RESULT: The tumor was progression after multi-line therapy including erlotinib, radiotherapy, combined chemotherapy and radioactive particles implantation. Pemetrexed monotherapy was applied and progression free survival of more than 5 months with partial remission (PR) response was achieved. Only 1 time of grade 3 neutropenia was observed during the pemetrexed chemotherapy. CONCLUSION: Due to the significant response and tolerability in the present case, pemetrexed monotherapy was recommended as a potent candidate for patients with advanced EMPD.
Authors: G V Scagliotti; C Gridelli; F de Marinis; M Thomas; M Dediu; J-L Pujol; C Manegold; B San Antonio; P M Peterson; W John; N Chouaki; C Visseren-Grul; L G Paz-Ares Journal: Lung Cancer Date: 2014-07-16 Impact factor: 5.705